The homopentameric α7-nAChR has been investigated as a potential therapeutic target for addressing cognitive impairments associated with neurological and psychiatric diseases, including Alzheimer's disease and schizophrenia (Wallace and Porter, 2011). Here, CHRNA7 is linked to early-onset autosomal dominant Alzheimer disease.